Planet Briefing

First published · Last updated

From Bad to Worse: The Clinical Spectrum of Immune Checkpoint Inhibitor Myocarditis and Associated 3M Syndrome with Concomitant Myositis and Myasthenia

Journal article (Hong Kong College of Cardiology) reporting the clinical spectrum of myocarditis linked to immune checkpoint inhibitors and an associated 3M syndrome with concomitant myositis and myasthenia. The supplied source metadata provides no additional case details or outcomes.

Figure 2. Immune checkpoint blockade of T-cell activity and mechanism of action of checkpoint inhibitors. The immune checkpoints regulate T-cell activity and are crucial for maintaining self-tolerance. However, in cancer, the endogenous T-cell immune checkpoints, CTLA-4 and PD-1, inhibit T-cell activity when bound to their ligands, CD80/86 (antigen-presenting cells) and PD-L1 (cancer cells), respectively. Treatments with checkpoint inhibitors can disrupt this regulatory interaction allowing T-ce
Illustrative image: Figure 2. Immune checkpoint blockade of T-cell activity and mechanism of action of checkpoint inhibitors. The immune checkpoints regulate T-cell activity and are crucial for maintaining self-tolerance. However, in cancer, the endogenous T-cell immune checkpoints, CTLA-4 and PD-1, inhibit T-cell activity when bound to their ligands, CD80/86 (antigen-presenting cells) and PD-L1 (cancer cells), respectively. Treatments with checkpoint inhibitors can disrupt this regulatory interaction allowing T-ce — Law, A.M.K.; Valdes-Mora, F.; Gallego-Ortega, D./Wikimedia Commons, CC BY 4.0

Categories: public-health, science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence
3/10
Geographic reach
1/10
Global importance
3/10
Impact magnitude
3/10
Positivity
2/10
Urgency
2/10

Why it matters

The title describes serious immune-related cardiac and neuromuscular conditions associated with cancer immunotherapy.

Sources

Report an issue